Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received an average rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $39.00.

Several research firms have recently commented on ARTV. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Needham & Company LLC restated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Finally, Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th.

Insider Buying and Selling

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32. Following the acquisition, the director directly owned 15,203,995 shares of the company’s stock, valued at $175,150,022.40. This represents a 74.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Corp. Gc acquired 1,085,069 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $11.52 per share, for a total transaction of $12,499,994.88. Following the acquisition, the insider directly owned 4,391,969 shares of the company’s stock, valued at $50,595,482.88. This trade represents a 32.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 9,907,958 shares of company stock valued at $107,688,019 and have sold 53,040 shares valued at $477,890. Corporate insiders own 21.40% of the company’s stock.

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics in the fourth quarter valued at about $341,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics during the fourth quarter worth about $174,000. Landscape Capital Management L.L.C. acquired a new position in Artiva Biotherapeutics during the third quarter worth about $112,000. BNP Paribas Financial Markets increased its holdings in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Artiva Biotherapeutics in the second quarter valued at about $58,000.

Artiva Biotherapeutics Trading Up 4.4%

Shares of ARTV stock opened at $11.55 on Thursday. The company has a market capitalization of $285.60 million, a P/E ratio of -3.26 and a beta of 2.16. The business’s 50 day moving average is $9.21 and its two-hundred day moving average is $7.67. Artiva Biotherapeutics has a twelve month low of $2.22 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, equities analysts predict that Artiva Biotherapeutics will post -2.45 earnings per share for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.